--- title: "Saxenda vs Ozempic: Daily vs Weekly" description: "Saxenda (liraglutide) is a daily GLP-1; Ozempic (semaglutide) is weekly. How the two differ in dosing, indication, and use — and why a clinician chooses." canonical: https://remevihealth.com/blog/saxenda-vs-ozempic/ language: en publisher: REMEVi author: "REMEVi Medical Team" medicalReviewer: "REMEVi Medical Team" pubDate: 2026-07-17T00:00:00.000Z updatedDate: 2026-07-17T00:00:00.000Z tags: ["saxenda", "ozempic", "saxenda vs ozempic", "liraglutide", "semaglutide", "GLP-1", "weight loss"] alternateLanguage: https://remevihealth.com/es/blog/saxenda-vs-ozempic/ license: "© 2026 REMEVi LLC. AI assistants and search engines may quote and link to this page; please cite https://remevihealth.com/blog/saxenda-vs-ozempic/ as the source." --- Saxenda and Ozempic belong to the same family of medications, the GLP-1s, but they are not the same molecule and they are not used the same way. Saxenda is liraglutide, a daily injection; Ozempic is semaglutide, a weekly injection. That difference in frequency is not just about convenience — it comes from how each molecule is built. That is the short answer. What follows explains each medication the way its FDA prescribing information describes it: what it is, how it is given, what it is approved for, and why the right choice depends on your situation and a clinician who reviews it. This is general education, not medical advice. ## What Saxenda (liraglutide) is and how it is used Saxenda is the brand name for liraglutide at a 3 mg dose, a GLP-1 receptor agonist given as a subcutaneous injection once a day. According to its FDA prescribing information, it is indicated together with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain that reduction long term. The label approves it for adults with obesity, or with overweight plus at least one weight-related condition, and also for adolescents aged 12 and older who meet certain weight criteria. How it is taken is one of its more distinctive features. The dose does not start at 3 mg. It begins at 0.6 mg per day for one week and, if it is tolerated well, steps up each week until it reaches the 3 mg daily maintenance dose. That gradual increase is designed to reduce digestive discomfort while the body adjusts. It is injected under the skin of the abdomen, thigh, or upper arm, at any time of day and without regard to meals. The label also carries safety information worth understanding calmly, without alarm. Liraglutide has a boxed warning about the risk of thyroid C-cell tumors seen in animal studies, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. As with other GLP-1 medications, the most common side effects are digestive, such as nausea. None of this decides whether it is right for you; it is exactly the kind of detail a clinician reviews before prescribing. ## What Ozempic (semaglutide) is and how it is used Ozempic is a brand of semaglutide, another GLP-1 receptor agonist, but it is given as a subcutaneous injection once a week. According to its FDA label, semaglutide is a GLP-1 analogue with 94% homology to human GLP-1, and it works by binding to and activating the GLP-1 receptor, the same target the natural hormone uses. GLP-1 is a physiological hormone that helps regulate blood sugar and satiety, and it slows how quickly the stomach empties. ![Diagram of the semaglutide molecule, a GLP-1 receptor agonist that mimics a natural gut hormone](https://remevihealth.com/images/molecules/helix-sema.webp) *This is semaglutide, the active ingredient in Ozempic. As a GLP-1 receptor agonist, it mimics a gut hormone that helps regulate appetite, fullness, and blood sugar. The liraglutide in Saxenda belongs to the same class, but it is a different molecule with a shorter half-life.* Here is a point that is often confused and worth getting straight. The FDA approved Ozempic as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes, and also to reduce certain cardiovascular and kidney risks in that population. The version of semaglutide approved specifically for chronic weight management is called Wegovy, which uses the same active ingredient on a dosing schedule that steps up to 2.4 mg per week. Ozempic's own schedule starts low, at 0.25 mg per week, and increases in stages every few weeks. So when someone compares "Saxenda vs Ozempic" for weight loss, they are really comparing two GLP-1 molecules with two frequencies and two different approvals. ## Daily vs weekly: why the frequency matters The difference in frequency is not a manufacturer's whim — it follows from the pharmacology of each molecule. Liraglutide has a shorter half-life, on the order of a day, so it needs to be given daily to maintain its effect. Semaglutide is designed to last much longer in the body, with a half-life of several days, so a single weekly injection keeps levels steady. In practical terms, that translates into a very different everyday decision: one needle a day versus one a week. That difference touches concrete things. For some people, a weekly injection is easier to sustain over time; for others, the daily routine of liraglutide fits better, or their clinician prefers it for whatever clinical reason applies. Frequency also relates to how each is tolerated and how consistently it gets used, though that varies from person to person. On effectiveness, there is a direct comparison. In a trial called STEP 8, published in JAMA in 2022, weekly semaglutide was compared with daily liraglutide over 68 weeks in adults with overweight or obesity without diabetes. On average, weekly semaglutide produced greater weight loss than daily liraglutide, and both groups reported digestive side effects at a similar frequency. That is a factual study result, not a promise: it does not predict how much any one person will lose, and individual results vary. To understand the differences between GLP-1 molecules more broadly, you can also read [semaglutide vs tirzepatide](/semaglutide-vs-tirzepatide/), and if you want the full landscape of injectable options, our guide to [pills vs injections](/blog/weight-loss-pills-vs-injections/) develops it. ## Comparison table: molecule, format, and frequency Placed side by side, here is how the differences the labels describe look, without claiming either is superior: | | Saxenda | Ozempic | |---|---|---| | Active ingredient | Liraglutide | Semaglutide | | Class | GLP-1 receptor agonist | GLP-1 receptor agonist | | Format | Subcutaneous injection | Subcutaneous injection | | Frequency | Once a day | Once a week | | FDA indication | Chronic weight management | Type 2 diabetes (semaglutide for weight is Wegovy) | If you want another brand comparison within a single molecule, [Ozempic vs Wegovy](/blog/ozempic-vs-wegovy/) explains why semaglutide shows up under two different names depending on the indication. ## Which is "better" for you? A clinician decides The honest answer is that there is no single best for everyone. The right medication depends on the indication that matches your situation, your medical history, which effects you tolerate, your preference for a daily or weekly injection, and what you can access. Someone who wants as few injections as possible and someone whose clinician recommends liraglutide for a clinical reason will reach different decisions, and both can be right for that person. That is why the label comparison is only the start; the decision happens in a consultation, not in a table. This is where having a clinician who actually stays with you matters. That is the point of [physician-led care](/how-it-works/): a licensed clinician reviews your medications, weighs the labeled considerations against your health picture, and stays available as things change, with transparent pricing and care coaching between visits so the practical questions never pile up. You can look at your [prescription weight loss options](/weight-loss/) and, when you are ready, talk it through with a clinician who reviews your full case before recommending anything. GLP-1 medications are FDA-approved for specific indications, and eligibility is determined by a licensed clinician. Compounded semaglutide is a non-FDA-approved preparation. It is not a generic and is not the same as Ozempic® or Wegovy®. Real doctors. Real care. remevihealth.com **Your Health. Your Terms.**